CN105233308B - 一种用于hifu的超声造影剂及其制备方法与应用 - Google Patents
一种用于hifu的超声造影剂及其制备方法与应用 Download PDFInfo
- Publication number
- CN105233308B CN105233308B CN201510730720.8A CN201510730720A CN105233308B CN 105233308 B CN105233308 B CN 105233308B CN 201510730720 A CN201510730720 A CN 201510730720A CN 105233308 B CN105233308 B CN 105233308B
- Authority
- CN
- China
- Prior art keywords
- contrast agent
- acoustic contrast
- hifu
- liposome
- fluorine carbon
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000002872 contrast media Substances 0.000 title claims abstract description 85
- 238000002360 preparation method Methods 0.000 title claims abstract description 18
- PRPAGESBURMWTI-UHFFFAOYSA-N [C].[F] Chemical compound [C].[F] PRPAGESBURMWTI-UHFFFAOYSA-N 0.000 claims abstract description 46
- 239000002502 liposome Substances 0.000 claims abstract description 36
- 239000007788 liquid Substances 0.000 claims abstract description 35
- 238000002604 ultrasonography Methods 0.000 claims abstract description 27
- 235000014103 egg white Nutrition 0.000 claims abstract description 22
- 210000000969 egg white Anatomy 0.000 claims abstract description 22
- NBVXSUQYWXRMNV-UHFFFAOYSA-N fluoromethane Chemical compound FC NBVXSUQYWXRMNV-UHFFFAOYSA-N 0.000 claims abstract description 19
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 claims abstract description 15
- 108010000912 Egg Proteins Proteins 0.000 claims abstract description 15
- 102000002322 Egg Proteins Human genes 0.000 claims abstract description 15
- 239000003085 diluting agent Substances 0.000 claims abstract description 8
- 210000004204 blood vessel Anatomy 0.000 claims abstract description 5
- 239000000243 solution Substances 0.000 claims description 49
- 239000002904 solvent Substances 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 7
- 230000002209 hydrophobic effect Effects 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 7
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical group ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 6
- 239000000463 material Substances 0.000 claims description 6
- 229960004624 perflexane Drugs 0.000 claims description 6
- ZJIJAJXFLBMLCK-UHFFFAOYSA-N perfluorohexane Chemical compound FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F ZJIJAJXFLBMLCK-UHFFFAOYSA-N 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 4
- 229910052731 fluorine Inorganic materials 0.000 claims description 4
- 150000002632 lipids Chemical class 0.000 claims description 4
- 239000011159 matrix material Substances 0.000 claims description 4
- 229920001223 polyethylene glycol Polymers 0.000 claims description 4
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 claims description 3
- 239000002202 Polyethylene glycol Substances 0.000 claims description 3
- -1 bromine alkane Chemical class 0.000 claims description 3
- 229910052799 carbon Inorganic materials 0.000 claims description 3
- 238000009826 distribution Methods 0.000 claims description 3
- 239000011737 fluorine Substances 0.000 claims description 3
- 239000002245 particle Substances 0.000 claims description 3
- 239000002504 physiological saline solution Substances 0.000 claims description 3
- 150000001335 aliphatic alkanes Chemical class 0.000 claims description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 2
- 229910052794 bromium Inorganic materials 0.000 claims description 2
- 238000005119 centrifugation Methods 0.000 claims description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims 3
- 125000002252 acyl group Chemical group 0.000 claims 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 235000011187 glycerol Nutrition 0.000 claims 1
- 229910052698 phosphorus Inorganic materials 0.000 claims 1
- 239000011574 phosphorus Substances 0.000 claims 1
- 210000002706 plastid Anatomy 0.000 claims 1
- 238000001556 precipitation Methods 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 27
- 230000002708 enhancing effect Effects 0.000 abstract description 11
- 206010028980 Neoplasm Diseases 0.000 abstract description 7
- 230000000451 tissue damage Effects 0.000 abstract description 4
- 231100000827 tissue damage Toxicity 0.000 abstract description 4
- 230000001052 transient effect Effects 0.000 abstract description 4
- 239000000203 mixture Substances 0.000 abstract description 3
- 238000003384 imaging method Methods 0.000 description 19
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 9
- 238000009835 boiling Methods 0.000 description 6
- KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 101100117236 Drosophila melanogaster speck gene Proteins 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 238000012544 monitoring process Methods 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 101001000212 Rattus norvegicus Decorin Proteins 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- FVJZSBGHRPJMMA-UHFFFAOYSA-N distearoyl phosphatidylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCCCCCCCCCCCC FVJZSBGHRPJMMA-UHFFFAOYSA-N 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000004880 explosion Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- LVNGJLRDBYCPGB-LDLOPFEMSA-N (R)-1,2-distearoylphosphatidylethanolamine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[NH3+])OC(=O)CCCCCCCCCCCCCCCCC LVNGJLRDBYCPGB-LDLOPFEMSA-N 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 238000002679 ablation Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000002059 diagnostic imaging Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000446 fuel Substances 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 240000002853 Nelumbo nucifera Species 0.000 description 1
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 1
- 235000006510 Nelumbo pentapetala Nutrition 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 229910018503 SF6 Inorganic materials 0.000 description 1
- ATBOMIWRCZXYSZ-XZBBILGWSA-N [1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (9e,12e)-octadeca-9,12-dienoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC ATBOMIWRCZXYSZ-XZBBILGWSA-N 0.000 description 1
- SORGEQQSQGNZFI-UHFFFAOYSA-N [azido(phenoxy)phosphoryl]oxybenzene Chemical compound C=1C=CC=CC=1OP(=O)(N=[N+]=[N-])OC1=CC=CC=C1 SORGEQQSQGNZFI-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000008081 blood perfusion Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000007872 degassing Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- BIABMEZBCHDPBV-UHFFFAOYSA-N dipalmitoyl phosphatidylglycerol Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCCCCCCCCCC BIABMEZBCHDPBV-UHFFFAOYSA-N 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000002961 echo contrast media Substances 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000001965 increasing effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000002558 medical inspection Methods 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-N n-hexadecanoic acid Natural products CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- SFZCNBIFKDRMGX-UHFFFAOYSA-N sulfur hexafluoride Chemical compound FS(F)(F)(F)(F)F SFZCNBIFKDRMGX-UHFFFAOYSA-N 0.000 description 1
- 229960000909 sulfur hexafluoride Drugs 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000002277 temperature effect Effects 0.000 description 1
- 238000001132 ultrasonic dispersion Methods 0.000 description 1
- 238000012285 ultrasound imaging Methods 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 238000009834 vaporization Methods 0.000 description 1
- 230000008016 vaporization Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 230000010148 water-pollination Effects 0.000 description 1
Landscapes
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims (17)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510730720.8A CN105233308B (zh) | 2015-11-02 | 2015-11-02 | 一种用于hifu的超声造影剂及其制备方法与应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510730720.8A CN105233308B (zh) | 2015-11-02 | 2015-11-02 | 一种用于hifu的超声造影剂及其制备方法与应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN105233308A CN105233308A (zh) | 2016-01-13 |
CN105233308B true CN105233308B (zh) | 2018-10-30 |
Family
ID=55031292
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510730720.8A Active CN105233308B (zh) | 2015-11-02 | 2015-11-02 | 一种用于hifu的超声造影剂及其制备方法与应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN105233308B (zh) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1129910A (zh) * | 1993-07-02 | 1996-08-28 | 分子生物***研究所 | 蛋白质包囊不溶性气体的微球及其制备并用作超声显影剂 |
WO2012143739A1 (en) * | 2011-04-21 | 2012-10-26 | University Of Ulster | Sonodynamic therapy |
US20150086611A1 (en) * | 2013-09-26 | 2015-03-26 | Samsung Electronics Co., Ltd. | Liposome including complex of hydrophobic active ingredient and polypeptide and use of the liposome |
-
2015
- 2015-11-02 CN CN201510730720.8A patent/CN105233308B/zh active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1129910A (zh) * | 1993-07-02 | 1996-08-28 | 分子生物***研究所 | 蛋白质包囊不溶性气体的微球及其制备并用作超声显影剂 |
WO2012143739A1 (en) * | 2011-04-21 | 2012-10-26 | University Of Ulster | Sonodynamic therapy |
US20150086611A1 (en) * | 2013-09-26 | 2015-03-26 | Samsung Electronics Co., Ltd. | Liposome including complex of hydrophobic active ingredient and polypeptide and use of the liposome |
Non-Patent Citations (1)
Title |
---|
"相变纳米超声造影剂增效HIFU治疗作用的研究",;周洋;《中国博士学位论文全文数据库-医药卫生科技辑》;20121115;第21页第20行-第23页第13行,第34页第11行-第36页第1行,第42页倒数第1-2行, * |
Also Published As
Publication number | Publication date |
---|---|
CN105233308A (zh) | 2016-01-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
You et al. | Nanoparticle-enhanced synergistic HIFU ablation and transarterial chemoembolization for efficient cancer therapy | |
Arvanitis et al. | Combined ultrasound and MR imaging to guide focused ultrasound therapies in the brain | |
Phillips et al. | Phase-shift perfluorocarbon agents enhance high intensity focused ultrasound thermal delivery with reduced near-field heating | |
Phenix et al. | High intensity focused ultrasound technology, its scope and applications in therapy and drug delivery | |
Zhang et al. | A multifunctional theranostic nanoagent for dual-mode image-guided HIFU/chemo-synergistic cancer therapy | |
Rabkin et al. | Biological and physical mechanisms of HIFU-induced hyperecho in ultrasound images | |
Kopechek et al. | Cavitation-enhanced MR-guided focused ultrasound ablation of rabbit tumors in vivo using phase shift nanoemulsions | |
CN104826140B (zh) | 一种载药硅脂质超声造影剂的制备方法和应用 | |
Yu et al. | The use of a microbubble agent to enhance rabbit liver destruction using high intensity focused ultrasound | |
Wang et al. | Melanin-loaded biocompatible photosensitive nanoparticles for controlled drug release in combined photothermal-chemotherapy guided by photoacoustic/ultrasound dual-modality imaging | |
Zhu et al. | Treatment of murine tumors using acoustic droplet vaporization-enhanced high intensity focused ultrasound | |
Lee et al. | Evaluating HIFU‐mediated local drug release using thermal strain imaging: Phantom and preliminary in‐vivo studies | |
Badea et al. | Contrast enhanced ultrasonography (CEUS) in the characterization of tumor microcirculation. Validation of the procedure in the animal experimental model. | |
ES2355038T3 (es) | Adyuvante de emulsión fluorocarbonada para terapia de hifu y su uso. | |
Crake et al. | Combined passive acoustic mapping and magnetic resonance thermometry for monitoring phase-shift nanoemulsion enhanced focused ultrasound therapy | |
Juang et al. | Controlled hyperthermia with high-intensity focused ultrasound and ultrasound contrast agent microbubbles in porcine liver | |
Kobayashi et al. | Influence of contrast ultrasonography with perflutren lipid microspheres on microvessel injury | |
Zhao et al. | Phase‐shift Perfluoropentane Nanoemulsions Enhance Pulsed High‐intensity Focused Ultrasound Ablation in an Isolated Perfused Liver System and Their Potential Value for Cancer Therapy | |
Guan et al. | Destructive effect of HIFU on rabbit embedded endometrial carcinoma tissues and their vascularities | |
Jia et al. | Estimating dynamic vascular perfusion based on Er-based lanthanide nanoprobes with enhanced down-conversion emission beyond 1500 nm | |
CN105233308B (zh) | 一种用于hifu的超声造影剂及其制备方法与应用 | |
US20180185485A1 (en) | Polymeric Nanoparticles for Enhancing HIFU-Induced Ablation | |
Zhang et al. | Acoustic wave sparsely-activated localization microscopy (awsalm): in vivo fast ultrasound super-resolution imaging using nanodroplets | |
CN105169420B (zh) | 一种新型射频诊疗剂及其制备方法 | |
Zhang et al. | Fast Acoustic Wave Sparsely Activated Localization Microscopy (Fast-AWSALM) Using Octafluoropropane N Anodroplets |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20200306 Address after: No.71, Dongpeng Avenue, Dongqu, economic and Technological Development Zone, Luogang District, Guangzhou City, Guangdong Province Patentee after: GUANGZHOU CONSUN PHARMACEUTICAL Co.,Ltd. Address before: 1068 No. 518055 Guangdong city in Shenzhen Province, Nanshan District City Xili University School Avenue Patentee before: SHENZHEN INSTITUTES OF ADVANCED TECHNOLOGY CHINESE ACADEMY OF SCIENCES |
|
TR01 | Transfer of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: An ultrasonic contrast agent for HIFU and its preparation method and Application Effective date of registration: 20210806 Granted publication date: 20181030 Pledgee: China Co. truction Bank Corp Guangzhou economic and Technological Development Zone sub branch Pledgor: GUANGZHOU CONSUN PHARMACEUTICAL Co.,Ltd. Registration number: Y2021980007376 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20230129 Granted publication date: 20181030 Pledgee: China Co. truction Bank Corp Guangzhou economic and Technological Development Zone sub branch Pledgor: GUANGZHOU CONSUN PHARMACEUTICAL Co.,Ltd. Registration number: Y2021980007376 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: An ultrasound contrast agent for HIFU and its preparation method and application Effective date of registration: 20230203 Granted publication date: 20181030 Pledgee: China Construction Bank Corporation Guangzhou Development Zone Branch Pledgor: GUANGZHOU CONSUN PHARMACEUTICAL Co.,Ltd. Registration number: Y2023980031974 |